111 related articles for article (PubMed ID: 38014187)
1. Dilated cardiomyopathy mutation in beta-cardiac myosin enhances actin activation of the power stroke and phosphate release.
Bodt SML; Ge J; Ma W; Rasicci DV; Desetty R; McCammon JA; Yengo CM
bioRxiv; 2023 Nov; ():. PubMed ID: 38014187
[TBL] [Abstract][Full Text] [Related]
2. Tail Length and E525K Dilated Cardiomyopathy Mutant Alter Human β-Cardiac Myosin Super-Relaxed State.
Duno-Miranda S; Nelson SR; Rasicci DV; Bodt SLM; Cirilo JA; Vang D; Sivaramakrishnan S; Yengo CM; Warshaw DM
bioRxiv; 2023 Dec; ():. PubMed ID: 38105932
[TBL] [Abstract][Full Text] [Related]
3. Tail length and E525K dilated cardiomyopathy mutant alter human β-cardiac myosin super-relaxed state.
Duno-Miranda S; Nelson SR; Rasicci DV; Bodt SML; Cirilo JA; Vang D; Sivaramakrishnan S; Yengo CM; Warshaw DM
J Gen Physiol; 2024 Jun; 156(6):. PubMed ID: 38709176
[TBL] [Abstract][Full Text] [Related]
4. Cardiomyopathy mutations impact the actin-activated power stroke of human cardiac myosin.
Tang W; Ge J; Unrath WC; Desetty R; Yengo CM
Biophys J; 2021 Jun; 120(11):2222-2236. PubMed ID: 33864791
[TBL] [Abstract][Full Text] [Related]
5. Dilated cardiomyopathy mutation E525K in human beta-cardiac myosin stabilizes the interacting-heads motif and super-relaxed state of myosin.
Rasicci DV; Tiwari P; Bodt SML; Desetty R; Sadler FR; Sivaramakrishnan S; Craig R; Yengo CM
Elife; 2022 Nov; 11():. PubMed ID: 36422472
[TBL] [Abstract][Full Text] [Related]
6. Dilated cardiomyopathy mutation in the converter domain of human cardiac myosin alters motor activity and response to omecamtiv mecarbil.
Tang W; Unrath WC; Desetty R; Yengo CM
J Biol Chem; 2019 Nov; 294(46):17314-17325. PubMed ID: 31578282
[TBL] [Abstract][Full Text] [Related]
7. Omecamtiv Mecarbil Enhances the Duty Ratio of Human β-Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle.
Swenson AM; Tang W; Blair CA; Fetrow CM; Unrath WC; Previs MJ; Campbell KS; Yengo CM
J Biol Chem; 2017 Mar; 292(9):3768-3778. PubMed ID: 28082673
[TBL] [Abstract][Full Text] [Related]
8. Dilated cardiomyopathy myosin mutants have reduced force-generating capacity.
Ujfalusi Z; Vera CD; Mijailovich SM; Svicevic M; Yu EC; Kawana M; Ruppel KM; Spudich JA; Geeves MA; Leinwand LA
J Biol Chem; 2018 Jun; 293(23):9017-9029. PubMed ID: 29666183
[TBL] [Abstract][Full Text] [Related]
9. Converter domain mutations in myosin alter structural kinetics and motor function.
Gunther LK; Rohde JA; Tang W; Walton SD; Unrath WC; Trivedi DV; Muretta JM; Thomas DD; Yengo CM
J Biol Chem; 2019 Feb; 294(5):1554-1567. PubMed ID: 30518549
[TBL] [Abstract][Full Text] [Related]
10. Two Classes of Myosin Inhibitors, Para-nitroblebbistatin and Mavacamten, Stabilize β-Cardiac Myosin in Different Structural and Functional States.
Gollapudi SK; Ma W; Chakravarthy S; Combs AC; Sa N; Langer S; Irving TC; Nag S
J Mol Biol; 2021 Nov; 433(23):167295. PubMed ID: 34627791
[TBL] [Abstract][Full Text] [Related]
11. Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes.
Alamo L; Ware JS; Pinto A; Gillilan RE; Seidman JG; Seidman CE; Padrón R
Elife; 2017 Jun; 6():. PubMed ID: 28606303
[TBL] [Abstract][Full Text] [Related]
12. Direct real-time detection of the actin-activated power stroke within the myosin catalytic domain.
Muretta JM; Petersen KJ; Thomas DD
Proc Natl Acad Sci U S A; 2013 Apr; 110(18):7211-6. PubMed ID: 23589853
[TBL] [Abstract][Full Text] [Related]
13. FRET and optical trapping reveal mechanisms of actin activation of the power stroke and phosphate release in myosin V.
Gunther LK; Rohde JA; Tang W; Cirilo JA; Marang CP; Scott BD; Thomas DD; Debold EP; Yengo CM
J Biol Chem; 2020 Dec; 295(51):17383-17397. PubMed ID: 33453985
[TBL] [Abstract][Full Text] [Related]
14. Divergent Molecular Phenotypes in Point Mutations at the Same Residue in Beta-Myosin Heavy Chain Lead to Distinct Cardiomyopathies.
Lehman SJ; Meller A; Solieva SO; Lotthammer JM; Greenberg L; Langer SJ; Greenberg MJ; Tardiff JC; Bowman GR; Leinwand L
bioRxiv; 2023 Jul; ():. PubMed ID: 37461648
[TBL] [Abstract][Full Text] [Related]
15. Impact of regulatory light chain mutation K104E on the ATPase and motor properties of cardiac myosin.
Rasicci DV; Kirkland O; Moonschi FH; Wood NB; Szczesna-Cordary D; Previs MJ; Wenk JF; Campbell KS; Yengo CM
J Gen Physiol; 2021 Jul; 153(7):. PubMed ID: 33891674
[TBL] [Abstract][Full Text] [Related]
16. Modulating Beta-Cardiac Myosin Function at the Molecular and Tissue Levels.
Tang W; Blair CA; Walton SD; Málnási-Csizmadia A; Campbell KS; Yengo CM
Front Physiol; 2016; 7():659. PubMed ID: 28119616
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers.
Anderson RL; Trivedi DV; Sarkar SS; Henze M; Ma W; Gong H; Rogers CS; Gorham JM; Wong FL; Morck MM; Seidman JG; Ruppel KM; Irving TC; Cooke R; Green EM; Spudich JA
Proc Natl Acad Sci U S A; 2018 Aug; 115(35):E8143-E8152. PubMed ID: 30104387
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of force-pCa relation in
Yuan CC; Kazmierczak K; Liang J; Ma W; Irving TC; Szczesna-Cordary D
Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35177471
[TBL] [Abstract][Full Text] [Related]
19. Mutating the converter-relay interface of Drosophila myosin perturbs ATPase activity, actin motility, myofibril stability and flight ability.
Kronert WA; Melkani GC; Melkani A; Bernstein SI
J Mol Biol; 2010 May; 398(5):625-32. PubMed ID: 20362584
[TBL] [Abstract][Full Text] [Related]
20. Myosin dilated cardiomyopathy mutation S532P disrupts actomyosin interactions, leading to altered muscle kinetics, reduced locomotion, and cardiac dilation in
Trujillo AS; Hsu KH; Puthawala J; Viswanathan MC; Loya A; Irving TC; Cammarato A; Swank DM; Bernstein SI
Mol Biol Cell; 2021 Aug; 32(18):1690-1706. PubMed ID: 34081531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
